World Lymphoma Therapeutics Market - Opportunities and Forecasts, 2014 - 2022. The report segments the lymphoma drugs market on the basis of cancer type, therapy type and geography.
Portland, OR -- (SBWIRE) -- 07/13/2017 -- Lymphoma comprises of a diverse group of blood cancers with different causes and treatment pathways. It is mainly categorized into two forms i.e., Hodgkin Lymphoma and non-Hodgkin Lymphoma (NHL). According to the American Cancer Society (ACS), NHL is one of the most frequently diagnosed cancer in the U.S. that represent 4% of all types of cancers.
"Early Buyers Will Receive 20% Customization on This Report."
The global lymphoma therapeutics market is set to witness an impressive growth, primarily due to high unmet clinical needs associated with the disease and emerging product launches. The NHL therapeutics market is the major market among global lymphoma therapeutics market. The promising drug pipeline and evolving treatment patterns are the factors that would largely drive the market growth. Rising prevalence of lymphoma, increasing funding from different governments, growing awareness and accelerated approvals offered by the regulatory authorities are the other factors that would propel the market growth. On the other hand, premium pricing of drugs, limited reimbursement and looming resistance toward the approved therapies would curtail the market growth.
Get Sample @ https://www.alliedmarketresearch.com/request-toc-and-sample/1448
The patent cliffs of blockbuster drugs would offer lucrative opportunities for new entrants and existing companies. Conversely, the emergence of resistance toward established therapies would remain as a key challenge for the drug innovators.
The market is expected to register substantial growth in mid-term due to the various strategies adopted by the leading industry players. One of the key strategies adopted is co-promotion and commercialization. Recently, EMD Serono entered into an agreement with Pfizer to co-promote its anaplastic lymphoma kinase (ALK) inhibitor Xalkori in the U.S. market.
Based on cancer type, the market is segmented into Hodgkin Lymphoma and non-Hodgkin Lymphoma (NHL). On the basis of therapy type, the market is segmented into targeted therapy, chemotherapy, immunotherapy and others. The report covers a geographic breakdown and a detailed analysis of each of the aforesaid segments across North America, Europe, Asia Pacific, and LAMEA.
Comprehensive competitive analysis and profiles of major market players such as F. Hoffmann-La Roche AG, Eli Lilly, Pfizer Inc., Bristol-Myers Squibb (BMS) and others are also provided in the report.
Send Enquiry @ https://www.alliedmarketresearch.com/purchase-enquiry/1448